Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Sold by Main Street Financial Solutions LLC

Main Street Financial Solutions LLC reduced its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 17.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,650 shares of the biotechnology company’s stock after selling 4,850 shares during the period. Main Street Financial Solutions LLC’s holdings in Capricor Therapeutics were worth $345,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CAPR. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics in the first quarter worth about $40,000. Vanguard Group Inc. boosted its position in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the period. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at approximately $147,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 12.00% of the company’s stock.

Analyst Upgrades and Downgrades

CAPR has been the topic of several analyst reports. Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler assumed coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday. Maxim Group boosted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Up 9.3 %

Shares of CAPR opened at $18.49 on Friday. The stock has a 50 day moving average price of $14.63 and a 200 day moving average price of $8.29. Capricor Therapeutics Inc has a one year low of $2.87 and a one year high of $23.40.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.